Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | -1.31 | 0.00 | 2.32 |
| FCF Yield | -0.15% | -0.35% | 0.01% | -0.52% |
| EV / EBITDA | -286.15 | -187.71 | -231.04 | -311.65 |
| Quality | ||||
| ROIC | -2.46% | -3.38% | -2.38% | -3.48% |
| Gross Margin | 89.76% | 91.26% | 92.96% | 93.17% |
| Cash Conversion Ratio | 0.77 | 1.01 | -0.03 | 2.24 |
| Growth | ||||
| Revenue 3-Year CAGR | 39.80% | 48.49% | 60.25% | 71.88% |
| Free Cash Flow Growth | 53.52% | -5,666.67% | 101.43% | -1,554.51% |
| Safety | ||||
| Net Debt / EBITDA | 9.97 | 11.50 | 24.53 | 6.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.78 | 0.65 | 0.57 | 0.62 |
| Cash Conversion Cycle | 76.14 | 152.45 | 101.35 | 121.64 |